CN104306390A - Application of reduced coenzyme II - Google Patents
Application of reduced coenzyme II Download PDFInfo
- Publication number
- CN104306390A CN104306390A CN201410570643.XA CN201410570643A CN104306390A CN 104306390 A CN104306390 A CN 104306390A CN 201410570643 A CN201410570643 A CN 201410570643A CN 104306390 A CN104306390 A CN 104306390A
- Authority
- CN
- China
- Prior art keywords
- nadph
- oral
- fatigue
- application according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 title claims abstract description 54
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 51
- 229920002527 Glycogen Polymers 0.000 claims abstract description 17
- 229940096919 glycogen Drugs 0.000 claims abstract description 16
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 10
- 230000002440 hepatic effect Effects 0.000 claims abstract description 6
- 230000001965 increasing effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 30
- 206010016256 fatigue Diseases 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000012937 correction Methods 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000009182 swimming Effects 0.000 abstract description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 9
- 235000014655 lactic acid Nutrition 0.000 abstract description 9
- 239000004310 lactic acid Substances 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 description 32
- 208000033042 Somatoform disorder cardiovascular Diseases 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 208000009157 neurocirculatory asthenia Diseases 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000003304 gavage Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to the biotechnology field and in particular relates to application of a reduced coenzyme II. Test results show that NADPH can be used for obviously prolonging weight-bearing swimming time of a mouse, increasing reserve of hepatic glycogen of a fatigued mouse and reducing lactic acid and urea nitrogen content of the fatigue mouse, so that the reduced coenzyme II has an obvious anti-fatigue effect.
Description
Technical field
The present invention relates to biological technical field, particularly the purposes of NADPH.
Background technology
Fatigue is a kind of sense of discomfort of subjectivity; main manifestations is feeling of fatigue, taediumvitae; can perceive working for a long time, under strenuous exercise or long-time stress; this is a kind of normal physiological protective reaction; prompting body should make functional recovery by rest, thus avoids the further injury to health.But along with the aggravation of social competition, the quickening of rhythm of life, makes people usually ignore fatigue, still select to work long hours.Be in fatigue state for a long time, meeting insulting muscle power, physical ability, health is unbalance, makes people be difficult to be engaged in or complete some comparatively large or that action is fine and smooth, the exquisite work that consumes one's strength, thus makes work efficiency drop; On the other hand, chronic fatigue also can make application on human skin relax, and lusterless complexion, presents the sign of geromorphism; Chronic fatigue can not get recovering, and make human immune system's functional disorder, even cause immunocompromised, the barrier of body resist the disease is broken, and the probability of patient is increased.In addition, long-term mental pressure, hormone disturbance, dysimmunity etc. are all the main inducing causing chronic fatigue syndrome.The work of over loading, excessive pressure and erratic daily life system make people usually feel, and feeling of fatigue, taediumvitae are difficult to recover for a long time, people are made to be in sub-health state for a long time, the people of 70% is about had to be in this state in crowd, wherein occurred frequently with middle-aged and elderly people again.
Based on this; need to find resisting fatigue material to delay long-time work, strenuous exercise or the fatigue that excessively causes under stress occurs; or make fatigue state return to normal condition as early as possible, recover normal to making people's sub-health state or curative effect is produced to fatigue syndrome.Existing anti-fatigue medicament is mainly based on Chinese medicine, and feature focuses on health preserving, and consumer needs long-term taking, and onset is slow.
Therefore, a kind of new anti-fatigue medicament is provided to have realistic meaning.
Summary of the invention
In view of this, the invention provides the purposes of NADPH.Result of the test shows, NADPH has and extends middle age and Aged Mice walking weight load, increase liver glycogen reserves, reduce lactic acid, urea nitrogen content, have that consumption is little, safety, injectable, can be oral etc. advantage, there is larger clinical value.
In order to realize foregoing invention object, the invention provides following technical scheme:
The invention provides NADPH (NADPH) and prepare the application in anti-fatigue medicament, health product or food.
The present invention studies display, and the free radical theory of exercise fatigue athletic injury is pointed out, the generation of kinetic free radical is the key factor causing organism fatigue.NADPH (NADPH) plays hydrogen carrier in many chemical reactions in vivo, result of study display NADPH treats ischemia apoplexy by antioxidation, and its antioxidation is mainly reflected in the scavenging action to oxygen radical.Also find that NADPH can participate in mitochondrion energy supply, participate in the function of hormone in vivo synthesis in addition, show that NADPH may have antifatigue effect.
Swimming with a load attached to the body is the important indicator evaluating body movement fatigue, and the length of swimming time can reflect the degree of animal movement fatigue.The glycogen of cylinder storage is the main energy sources of mouse movement, and body strenuous exercise needs to consume a large amount of glycogen, and therefore glycogen deposit is also the important indicator evaluating body fatigue resistance.Lactic acid occupies an important position in body energy supply system, and it is the end product of glycolysis energy supply, is again the important oxygen metabolism substrate in aerobic metabolism energy supplying system, and lactic acid can in liver by sugar heteroplasia role transformation be glucose energy supply.If but produce excessive lactic acid in body. H in muscle can be made
+concentration rising .pH declines, and then causes a series of Biochemical changes, will cause fatigue.Research display, the increase of blood urea nitrogen (BUN) and body are negative correlation to load performance, and body BUN content increases with the increase of sports load, so BUN is ideal, sensitive fatigue index.
In some embodiments of the invention, described resisting fatigue is for correcting sub-health state or treatment chronic fatigue syndrome.
In some embodiments of the invention, described correction sub-health state is for increasing hepatic glycogen content, increasing full blood lactic content or reduce Plasma Urea nitrogen content.
As preferably, NADPH provided by the invention is prepared in the purposes of anti-fatigue medicament, and described medicine also comprises pharmaceutically acceptable adjuvant.
In some embodiments of the invention, the preparation method of described medicine: be dissolved in by a certain amount of NADPH in normal saline or deionized water, can apply separately or form compound formulation with other active substance.
In some embodiments of the invention, the dosage form of described medicine is oral instant medicine film, oral liquid, beverage, tablet, capsule, spray, injection or cutaneous permeable agent.Find through test, the feature of NADPH (NADPH) resisting fatigue is not by the impact of dosage form, and the acceptable dosage form of any medicine all can reach close effect, and all within protection scope of the present invention, the present invention is in this no limit.
In some embodiments of the invention, the administering mode of described medicine is every day 1 ~ 3 time, each 1 ~ 100mg NADPH/kg the weight of animals.
In some embodiments of the invention, the administering mode of described medicine is injection or oral.The acceptable administering mode of any medicine all can reach close effect, and all within protection scope of the present invention, the present invention is in this no limit.
The invention provides NADPH (NADPH) and prepare the application in anti-fatigue medicament, health product or food.Test shows, lumbar injection gives NADPH and has the trend extending the mice burden swimming time, and this trend is dose dependent; Compared with control group, after the oral NADPH of giving the mice burden swimming time present dose dependent extend, Analysis of variance, in, heavy dose of group have significant difference (p<0.05) compared with control matched group.Compared with control group, the mice burden swimming time of model group obviously declines, and after the oral NADPH of giving the mice burden swimming time have obvious prolongation compared with model group.
Compared with control group, no matter be injection or orally give NADPH, Mouse Liver glycogen content all significantly increases, wherein, in drug administration by injection, dosage group and matched group difference reach significance level (Fig. 2 A), oral administration heavy dose group reaches significant level (Fig. 2 B) with matched group difference, there is statistical significance (p<0.05), in the experiment for the treatment of chronic effort syndromes models, oral administration small dose group and model group difference reach significant level (Fig. 2 C), have statistical significance (p<0.05).
After injection gives NADPH, compare with control group, full blood lactic content obviously declines, with middle dosage and heavy dose the most remarkable (p<0.05); Compared with control group, after the oral NADPH of giving, full blood lactic content declines all to some extent, but not statistically significant (p>0.05).Compared with model group, after the oral NADPH of giving, Mouse whole blood lactic acid content has obvious prolongation, has statistically significant meaning (p<0.01).
NADPH each dosage group Plasma Urea nitrogen content comparatively control group is compared and is declined all to some extent.In Analysis of variance drug administration by injection (Fig. 4 A), dosage group and matched group have highly significant, oral administration (Fig. 4 B) heavy dose group has highly significant (p<0.05) with matched group, oral administration treating chronic effort syndrome (Fig. 4 C) heavy dose of group has downward trend compared with model group, but not statistically significant.
Comprehensive above-mentioned experimental result, NADPH obviously can extend the mice burden swimming time, improves tired mice liver glycogen reserves, reduce tired mice lactic acid and urea nitrogen content, and prompting the present invention has obvious antifatigue effect.
The treatment of NADPH resisting fatigue syndrome obtains similar effect.
Accompanying drawing explanation
Fig. 1 shows the impact of NADPH on the mice burden swimming time; Wherein Figure 1A is first lumbar injection experimental result; Figure 1B is the oral experimental result of second batch, and * represents that p<0.05 and control group compares; Fig. 1 C is the 3rd batch of oral treating chronic effort syndrome experimental result;
Fig. 2 represents the impact of NADPH on mice liver glycogen reserves; Wherein Fig. 2 A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; Fig. 2 B is the oral experimental result of second batch, and * represents p<0.05, compares with control group; Fig. 2 C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * represents p<0.05, compares with model group;
Fig. 3 represents the impact of NADPH on Mouse whole blood lactate level; Wherein Fig. 3 A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; Fig. 3 B is the oral experimental result of second batch, and Fig. 3 C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * * represents p<0.01, compares with model group;
Fig. 4 represents the impact of NADPH on mice plasma urea nitrogen levels; Wherein A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; B is the oral experimental result of second batch, and * represents p<0.05, compares with control group; C is the 3rd batch of oral treating chronic effort syndrome experimental result.
Detailed description of the invention
The invention discloses the purposes of NADPH, those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.Method of the present invention and application are described by preferred embodiment, related personnel obviously can not depart from content of the present invention, spirit and scope methods and applications as herein described are changed or suitably change with combination, realize and apply the technology of the present invention.
In the purposes of NADPH provided by the invention, former medicine used and adjuvant, preparation all can be buied by market.
Below in conjunction with embodiment, set forth the present invention further:
Embodiment 1
1 materials and methods
1.1 samples:
1.2 laboratory animals: middle age age in May male ICR mouse; Age in August Old Male C57 mice.
1.3 instruments and reagent: the long microplate reader of swimming trunk, galvanized wire, all-wave, constant water bath box, centrifuge, hepatic glycogen detection kit (build up by Nanjing, article No. A043), lactate acid detection kit (build up by Nanjing, article No. A019-1), blood urea nitrogen test kit (build up by Nanjing, article No. C013-1), SOD detection kit (build up by Nanjing, article No. A001-1), MDA detection kit (Nanjing is built up, article No. A003-1).
1.4 experimental techniques:
A. first: by 60 the middle age in male age in May ICR mice be divided into 4 groups at random, often organize 15.The medicine of small dose group intraperitoneal injection 2.5mg/kg, the medicine of middle dosage intraperitoneal injection 5mg/kg, the medicine of heavy dose of intraperitoneal injection 10mg/kg.Control group gives the normal saline of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
B. second batch: old for 100 male ages in August C57 mice is divided into 4 groups at random, often organizes 20.The medicine of small dose group gavage 2.5mg/kg, the medicine of middle dosage gavage 5mg/kg, the medicine of heavy dose of gavage 10mg/kg.Control group gives the water of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
C. the 3rd batch: by 80 the middle age in male age in May ICR mice be divided into 4 groups at random, often organize 20.Raise 14 days under Control group home; its excess-three group carries out chronic fatigue syndrome modeling: every morning, 9:00 to 11:00 fettered, each one hour, and it is 35cm that mice is put into the depth of water by every afternoon; water temperature is force swimming 1 hour, continuous modeling 14 days in the swimming trunk of 21 ± 1 DEG C.Administration from the 15th day, the medicine of low dose of gavage 5mg/kg, the medicine of heavy dose of gavage 10mg/kg.Control group gives the water of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
1.4.1 swimming with a load attached to the body experiment
After last gives medicine 30min, bear the galvanized wire of 4% quality of its body weight to mouse tail.Mice being put into the depth of water is 35cm, and water temperature is the interior swimming of swimming trunk of 21 ± 1 DEG C, until power exhausts.The criterion that power exhausts is do not emerge in mouse head submerged 10s, and record power exhausts the time.
1.4.2 hepatic glycogen measures
After mice burden swimming, have a rest 10 minutes, by sacrifice after plucking eyeball blood sampling.Take out liver, blot with filter paper again with after normal saline rinsing, accurately take 50mg liver.The mensuration of liver hepatic glycogen is carried out according to test kit description.
1.4.3 full blood lactic measures
After mice burden swimming, have a rest 10 minutes, extract eyeball and get blood, the mensuration of carrying out full blood lactic is described according to test kit.
1.4.4 blood plasma index determining
After mice burden swimming, have a rest 10 minutes, eyeball is taken a blood sample, and with 3500 leaving the heart and isolate blood plasma after 10 minutes after the anticoagulant of EDETATE SODIUM salt, carries out the mensuration of plasma urea nitrogen according to test kit description.
2 results
2.1 mice burden swimming timings
Fig. 1 represents the impact of NADPH on the mice burden swimming time.Wherein A is first lumbar injection experimental result; B is the oral experimental result of second batch, and * represents that p<0.05 and control group compares; C is the 3rd batch of oral treating chronic effort syndrome experimental result.As can be seen from Figure 1A, lumbar injection gives NADPH and has the trend extending the mice burden swimming time, and this trend is dose dependent; As can be seen from Figure 1B, compared with control group, after the oral NADPH of giving the mice burden swimming time present dose dependent extend, Analysis of variance, in, heavy dose of group have significant difference (p<0.05) compared with control matched group.As can be seen from Fig. 1 C, compared with control group, the mice burden swimming time of model group obviously declines, and after the oral NADPH of giving the mice burden swimming time have obvious prolongation compared with model group.
2.2 Mouse Liver glycogens measure
Fig. 2 represents the impact of NADPH on mice liver glycogen reserves, and wherein A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; B is the oral experimental result of second batch, and * represents p<0.05, compares with control group; C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * represents p<0.05, compares with model group.As seen from Figure 2, compared with control group, no matter be injection or orally give NADPH, Mouse Liver glycogen content all significantly increases, wherein, in drug administration by injection, dosage group and matched group difference reach significance level (Fig. 2 A), oral administration heavy dose group reaches significant level (Fig. 2 B) with matched group difference, there is statistical significance (p<0.05), in the experiment for the treatment of chronic effort syndromes models, oral administration small dose group and model group difference reach significant level (Fig. 2 C), there is statistical significance (p<0.05).
2.3 Mouse whole blood Plasma lactates
Fig. 3 represents the impact of NADPH on Mouse whole blood lactate level.Wherein A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; B is the oral experimental result of second batch, and C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * * represents p<0.01, compares with model group.As can be seen from Fig. 3 A, after injection gives NADPH, compare with control group, full blood lactic content obviously declines, with middle dosage and heavy dose the most remarkable (p<0.05); As can be seen from Fig. 3 B, compared with control group, after the oral NADPH of giving, full blood lactic content declines all to some extent, but not statistically significant (p>0.05).As can be seen from Fig. 3 C, compared with model group, after the oral NADPH of giving, Mouse whole blood lactic acid content has obvious prolongation, has statistically significant meaning (p<0.01).
2.4 mice plasma urea nitrogen contents measure
Fig. 4 represents the impact of NADPH on mice plasma urea nitrogen levels.Wherein A is first lumbar injection experimental result, and * represents p<0.05, compares with control group; B is the oral experimental result of second batch, and * represents p<0.05, compares with control group; C is the 3rd batch of oral treating chronic effort syndrome experimental result.As seen from Figure 4, NADPH each dosage group Plasma Urea nitrogen content comparatively control group compare and decline all to some extent.In Analysis of variance drug administration by injection (Fig. 4 A), dosage group and matched group have highly significant, oral administration (Fig. 4 B) heavy dose group has highly significant (p<0.05) with matched group, oral administration treating chronic effort syndrome (Fig. 4 C) heavy dose of group has downward trend compared with model group, but not statistically significant.
Comprehensive above-mentioned experimental result, NADPH obviously can extend the mice burden swimming time, improves tired mice liver glycogen reserves, reduce tired mice lactic acid and urea nitrogen content, and prompting the present invention has obvious antifatigue effect.
The treatment of NADPH resisting fatigue syndrome obtains similar effect.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. NADPH is preparing the application in anti-fatigue medicament, health product or food.
2. application according to claim 1, is characterized in that, described resisting fatigue is for correcting sub-health state or treatment chronic fatigue syndrome.
3. application according to claim 1, is characterized in that, described correction sub-health state is for increasing hepatic glycogen content, increasing full blood lactic content or reduce Plasma Urea nitrogen content.
4. application according to claim 1, is characterized in that, described medicine also comprises pharmaceutically acceptable adjuvant.
5. application according to claim 1, is characterized in that, the dosage form of described medicine is oral instant medicine film, oral liquid, beverage, tablet, capsule, spray, injection or cutaneous permeable agent.
6. application according to claim 1, is characterized in that, the administering mode of described medicine is every day 1 ~ 3 time, each 1 ~ 100mg NADPH/kg the weight of animals.
7. application according to claim 6, is characterized in that, the administering mode of described medicine is injection or oral.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410570643.XA CN104306390A (en) | 2014-10-23 | 2014-10-23 | Application of reduced coenzyme II |
| PCT/CN2015/083890 WO2016062125A1 (en) | 2014-10-23 | 2015-07-13 | Use of reduced coenzyme ii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410570643.XA CN104306390A (en) | 2014-10-23 | 2014-10-23 | Application of reduced coenzyme II |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306390A true CN104306390A (en) | 2015-01-28 |
Family
ID=52361801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410570643.XA Pending CN104306390A (en) | 2014-10-23 | 2014-10-23 | Application of reduced coenzyme II |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104306390A (en) |
| WO (1) | WO2016062125A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840479A (en) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Application of NADPH in preparation of drugs used for treating heart diseases |
| WO2016062125A1 (en) * | 2014-10-23 | 2016-04-28 | 苏州人本药业有限公司 | Use of reduced coenzyme ii |
| CN109453300A (en) * | 2018-12-29 | 2019-03-12 | 雨润慕德生物科技（连云港）有限公司 | A kind of extracting method and its application of macamide and glucosinolate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| CN1299283A (en) * | 1998-04-17 | 2001-06-13 | 希格马托保健科学股份公司 | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH |
| CN1713916A (en) * | 2002-11-19 | 2005-12-28 | 奴洛皮亚生态营养医学研究有限公司 | NADH/NADPH-containing compound |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306390A (en) * | 2014-10-23 | 2015-01-28 | 苏州人本药业有限公司 | Application of reduced coenzyme II |
-
2014
- 2014-10-23 CN CN201410570643.XA patent/CN104306390A/en active Pending
-
2015
- 2015-07-13 WO PCT/CN2015/083890 patent/WO2016062125A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| CN1299283A (en) * | 1998-04-17 | 2001-06-13 | 希格马托保健科学股份公司 | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH |
| CN1713916A (en) * | 2002-11-19 | 2005-12-28 | 奴洛皮亚生态营养医学研究有限公司 | NADH/NADPH-containing compound |
Non-Patent Citations (3)
| Title |
|---|
| 佟欣: "《亚健康与中医心身医学》", 30 June 2014, 中国中医药出版社 * |
| 李卫彬等: "慢性疲劳综合征与亚健康状态", 《中华中医药学刊》 * |
| 高伟博等: "人参及其炮制品抗疲劳作用", 《中国实验方剂学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016062125A1 (en) * | 2014-10-23 | 2016-04-28 | 苏州人本药业有限公司 | Use of reduced coenzyme ii |
| CN104840479A (en) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Application of NADPH in preparation of drugs used for treating heart diseases |
| CN109453300A (en) * | 2018-12-29 | 2019-03-12 | 雨润慕德生物科技（连云港）有限公司 | A kind of extracting method and its application of macamide and glucosinolate |
| CN109453300B (en) * | 2018-12-29 | 2021-05-14 | 雨润慕德生物科技（连云港）有限公司 | Extraction method and application of macamide and glucosinolate |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016062125A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Effects of chronic dietary nitrate supplementation on the hemodynamic response to dynamic exercise | |
| CN104026563A (en) | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof | |
| CN102450718B (en) | Pulse sports beverage and preparation method thereof | |
| CN104306390A (en) | Application of reduced coenzyme II | |
| CN104740451B (en) | A kind of Chinese medicine composition for treating hyperuricemia and its application | |
| Dudgeon et al. | The effects of high and low-dose Cordyceps Militaris-containing mushroom blend supplementation after seven and twenty-eight days | |
| CN102210699A (en) | Use of chitosan oligosaccharide in preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN105213456A (en) | A kind of anti-fatigue medicament and its production and use | |
| Morita et al. | Clinical evaluation of changes in biomarkers by oral intake of NMN. | |
| CN102283382A (en) | Anti-aging health-care product and preparation method thereof | |
| Abou Farha et al. | Dopamine D2R agonist-induced cardiovascular effects in healthy male subjects: potential implications in clinical settings | |
| CN104083391A (en) | Application of cornflower-3-oxo-glucoside in medicines for treating obesity and related diseases | |
| CN104587151A (en) | Traditional Chinese medicine composite used for releasing fatigue as well as preparation method and application of traditional Chinese medicine composite | |
| Cheng et al. | Exercise in type 2 diabetes: The mechanisms of resistance and endurance training | |
| Noé et al. | Cardiovascular results of an individually controlled complex prevention | |
| CN114191422A (en) | Application of phloretin in preparation of antidepressant drugs | |
| CN103622988B (en) | Cordycepin purposes in the medicine preparing depression and the Fast Anti antidepressant agents being prepared thereof | |
| Kumar et al. | Effect of coffee on blood pressure and electrocardiographic changes in young and elderly healthy subjects | |
| Sudhakar et al. | Serum creatine kinase response on exercise induced delayed onset muscle soreness: a pilot single blind randomized clinical trial | |
| CN103860578A (en) | Use of lentinan as antidepressant drug | |
| Wu | Hydrogen-rich Water Improves the Physical Ability of Football Players and the Anti-fatigue Ability of Rats. | |
| Hosseini et al. | The effect of resistance training on glycemic indexes of streptozotocin induced diabetic rats | |
| Bashyal et al. | Effectiveness of physioball exercises on glucose level, cardiovascular fitness and quality of life in patients with type 2 diabetes mellitus | |
| CN105395680B (en) | It is a kind of to treat neurasthenic Chinese medicine composition and its preparation method and application | |
| CN102935094A (en) | Composite for diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150128 |
|
| RJ01 | Rejection of invention patent application after publication |